Top

Published in:

01-03-2005 | Article

Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition

Authors: C. Poitou, N. Viguerie, R. Cancello, R. De Matteis, S. Cinti, V. Stich, C. Coussieu, E. Gauthier, M. Courtine, J. D. Zucker, G. S. Barsh, W. Saris, P. Bruneval, A. Basdevant, D. Langin, K. Clément

Published in: Diabetologia | Issue 3/2005

Abstract

Aims/hypothesis

The acute-phase proteins, serum amyloid As (SAA), are precursors of amyloid A, involved in the pathogenesis of AA amyloidosis. This work started with the characterisation of systemic AA amyloidosis concurrent with SAA overexpression in the subcutaneous white adipose tissue (sWAT) of an obese patient with a leptin receptor deficiency. In the present study a series of histopathological, cellular and gene expression studies was performed to assess the importance of SAA in common obesity and its possible production by mature adipocytes.

Materials and methods

Gene expression profiling was performed in the sWAT of two extremely obese patients with a leptin receptor deficiency. Levels of the mRNAs of the different SAA isoforms were quantified in sWAT cellular fractions from lean subjects and from obese subjects before and after a very-low-calorie diet. These values were subsequently compared with serum levels of SAA in these individuals. In addition, histopathological analyses of sWAT were performed in lean and obese subjects.

Results

In sWAT, the expression of SAA is more than 20-fold higher in mature adipocytes than in the cells of the stroma vascular fraction (p<0.01). Levels of SAA mRNA expression and circulating levels of the protein are sixfold (p<0.001) and 3.5-fold (p<0.01) higher in obese subjects than in lean subjects, respectively. In lean subjects, 5% of adipocytes are immunoreactive for SAA, whereas the corresponding value is greater than 20% in obese subjects. Caloric restriction results in decreases of 45–75% in levels of the transcripts for the SAA isoforms and in circulating levels of the protein.

Conclusions/interpretation

The results of the present study indicate that SAA is expressed by sWAT, and its production at this site is regulated by nutritional status. If amyloidosis is seen in the context of obesity, it is possible that production of SAA by adipocytes could be a contributory factor.

Available only for authorised users

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–2135CrossRefPubMed

Engeli S, Feldpausch M, Gorzelniak K et al (2003) Association between adiponectin and mediators of inflammation in obese women. Diabetes 52:942–947

van Dielen FM, van’t Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW (2001) Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 25:1759–1766CrossRef

Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB (1999) Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 20:954–959CrossRef

Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F (1999) Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 99:2221–2222

Marette A (2002) Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care 5:377–383CrossRefPubMed

Lyon CJ, Law RE, Hsueh WA (2003) Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144:2195–2200CrossRef

Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214CrossRefPubMed

Theuma P, Fonseca VA (2003) Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Curr Diab Rep 3:248–254

10.

Gomez-Ambrosi J, Fruhbeck G (2001) Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med 135:306–307

11.

Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD (2001) Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 175:81–92CrossRefPubMed

12.

Rajala MW, Scherer PE (2003) Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765–3773PubMed

13.

Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349–356PubMed

14.

Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830CrossRefPubMed

15.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808CrossRefPubMed

16.

Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126CrossRefPubMed

17.

Arsenijevic D, Onuma H, Pecqueur C et al (2000) Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet 26:435–439CrossRefPubMed

18.

Clement K, Vaisse C, Lahlou N et al (1998) A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392:398–401CrossRefPubMed

19.

Clement K, Vega N, Laville M et al (2002) Adipose tissue gene expression in patients with a loss of function mutation in the leptin receptor. Int J Obes Relat Metab Disord 26:1533–1538CrossRef

20.

Clement K, Viguerie N, Diehn M et al (2002) In vivo regulation of human skeletal muscle gene expression by thyroid hormone. Genome Res 12:281–291CrossRef

21.

Rome S, Clement K, Rabasa-Lhoret R et al (2003) Microarray profiling of human skeletal muscle reveals that insulin regulates approximately 800 genes during a hyperinsulinemic clamp. J Biol Chem 278:18063–18068CrossRef

22.

Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116–5121

23.

Viguerie N, Millet L, Avizou S, Vidal H, Larrouy D, Langin D (2002) Regulation of human adipocyte gene expression by thyroid hormone. J Clin Endocrinol Metab 87:630–634CrossRef

24.

Cinti S, Zingaretti MC, Cancello R, Ceresi E, Ferrara P (2001) Morphologic techniques for the study of brown adipose tissue and white adipose tissue. Methods Mol Biol 155:21–51

25.

McDonald TL, Weber A, Smith JW (1991) A monoclonal antibody sandwich immunoassay for serum amyloid A (SAA) protein. J Immunol Methods 144:149–155CrossRef

26.

Drenth JP, van der Meer JW (2001) Hereditary periodic fever. N Engl J Med 345:1748–1757CrossRefPubMed

27.

Grateau G (2004) Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford) 43:410–415

28.

Hoffman HM, Wanderer AA, Broide DH (2001) Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108:615–620CrossRef

29.

Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7:64–69CrossRef

30.

Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583–596CrossRef

31.

Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE (2001) Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 276:42077–42083CrossRef

32.

Soukas A, Cohen P, Socci ND, Friedman JM (2000) Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev 14:963–980

33.

Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC (1986) Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 261:9644–9651

34.

Kindy MS, de Beer MC, Yu J, de Beer FC (2000) Expression of mouse acute-phase (SAA1.1) and constitutive (SAA4) serum amyloid A isotypes: influence on lipoprotein profiles. Arterioscler Thromb Vasc Biol 20:1543–1550

35.

Hamano M, Saito M, Eto M et al (2004) Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease. Ann Clin Biochem 41:125–129CrossRef

36.

Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR (2003) Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166:387–394CrossRefPubMed

37.

Walder K, Kantham L, McMillan JS et al (2002) Tanis: a link between type 2 diabetes and inflammation? Diabetes 51:1859–1866

38.

Karlsson HK, Tsuchida H, Lake S, Koistinen HA, Krook A (2004) Relationship between serum amyloid A level and Tanis/SelS mRNA expression in skeletal muscle and adipose tissue from healthy and type 2 diabetic subjects. Diabetes 53:1424–1428

39.

Naeser P, Westermark P (1977) Amyloidosis in ageing obese-hyperglycemic mice and their lean litter-mates. A morphological study. Acta Pathol Microbiol Scand A 85:761–767

40.

Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24–29CrossRefPubMed

41.

Buxbaum JN, Tagoe CE (2000) The genetics of the amyloidoses. Annu Rev Med 51:543–569CrossRef

42.

Migita K, Yamasaki S, Shibatomi K et al (2001) Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Immunol 123:408–411CrossRef

43.

Falk RH, Comenzo RL, Skinner M (1997) The systemic amyloidoses. N Engl J Med 337:898–909CrossRefPubMed

44.

Adelman RD (2002) Obesity and renal disease. Curr Opin Nephrol Hypertens 11:331–335CrossRef

45.

de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL (2002) Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 26(Suppl 4):S21–S24CrossRef

Title: Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition
Authors: C. Poitou
N. Viguerie
R. Cancello
R. De Matteis
S. Cinti
V. Stich
C. Coussieu
E. Gauthier
M. Courtine
J. D. Zucker
G. S. Barsh
W. Saris
P. Bruneval
A. Basdevant
D. Langin
K. Clément
Publication date: 01-03-2005
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 3/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-004-1654-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 3/2005

Low birthweight is associated with specific changes in muscle insulin-signalling protein expression

Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia

Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity

The mitochondrial rhomboid protease PSARL is a new candidate gene for type 2 diabetes

Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α

EEG abnormalities with and without relation to severe hypoglycaemia in adolescents with type 1 diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page